Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04837547 · ClinicalTrials.gov registry record · Phase 1
PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy
A Phase 1 study of Neuroblastoma and Diffuse Intrinsic Pontine Glioma, sponsored by University of Florida.
- Active
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 3
- Study locations
NCT04837547: Active Phase 1 study of Neuroblastoma and Diffuse Intrinsic Pontine Glioma, sponsored by University of Florida.
NCT04837547 is a Phase 1 study of Neuroblastoma and Diffuse Intrinsic Pontine Glioma that is active but no longer recruiting, run by University of Florida. The registered enrollment target is 24 participants, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (90% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04837547, a Phase 1 study of Neuroblastoma and Diffuse Intrinsic Pontine Glioma, is active but no longer recruiting, sponsored by University of Florida.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 3
- Study locations
Study Summary
A Phase I open-label, multicenter study, to evaluate the safety, feasibility, and maximum tolerated dose (MTD) of treating children with newly diagnosed DIPG or recurrent neuroblastoma with molecular targeted therapy in combination with adoptive cell therapy (Total tumor mRNA-pulsed autologous Dendritic Cells (DCs) (TTRNA-DCs), Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT) and Autologous G-CSF mobilized Hematopoietic Stem Cells (HSCs)).
Primary Outcome
To evaluate the dose-limiting toxicities (DLTs) and to establish the maximum tolerated dose (MTD) of treating children with molecular targeted therapy in combination with adoptive cellular therapy
Conditions Studied
Interventions
- BIOLOGICAL Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT)
Study Locations (3)
Florida
- University of Florida - Gainesville
North Carolina
- Levine Children's Hospital - Charlotte
Pennsylvania
- Penn State Milton S. Hershey Medical Center and Children's Hospital - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-09-20 |
| Est. Completion | 2032-09 |
| Phase | Phase 1 |
What the registry record for NCT04837547 still lists
NCT04837547 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Neuroblastoma appearing as the primary indexed condition, and to 1 intervention - of which Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT) is the first listed.
NCT04837547 reports a single indexed study location in Florida, North Carolina, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04837547 about?
NCT04837547 is a clinical study titled "PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy". A Phase I open-label, multicenter study, to evaluate the safety, feasibility, and maximum tolerated dose (MTD) of treating children with newly diagnosed DIPG or recurrent neuroblastoma with molecular targeted therapy in combination with adoptive cell therapy (Total tumor mRNA-pulsed autologous Dendr...
What is the current status of trial NCT04837547?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2021-09-20. Estimated completion is 2032-09.
What conditions does trial NCT04837547 study?
This clinical trial studies the following conditions: Neuroblastoma, Diffuse Intrinsic Pontine Glioma.
What interventions are being tested in trial NCT04837547?
The interventions under investigation include: Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04837547?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04837547 being conducted?
This trial has 3 study locations across Florida, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04837547's enrollment target sits among peer trials
24 67th of 94 higher than 27 of 94 other Neuroblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
RECRUITING · Phase 1
-
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RECRUITING · Phase 1
-
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI